RedHill Biopharma Ltd. [RDHL] moved up 1.37: Why It’s Important

RedHill Biopharma Ltd. [NASDAQ: RDHL] surged by $0.0 during the normal trading session on Monday and reaching a high of $0.6351 during the day while it closed the day at $0.50. The company report on August 17, 2022 that RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Developed as the first stand-alone standard of care first-line therapy for NTM disease caused by Mycobacterium avium complex (MAC) infection, RHB-204 is currently undergoing a Phase 3 study in the U.S.

EMA Orphan Drug Designation provides eligibility for 10 years post-approval EU market exclusivity. U.S. FDA Fast Track, Orphan and QIDP priority designations, previously granted to RHB-204, extend U.S. post-approval market exclusivity to a total of 12 years.

RedHill Biopharma Ltd. stock has also loss -25.45% of its value over the past 7 days. However, RDHL stock has declined by -50.66% in the 3 months of the year. Over the past six months meanwhile, it has lost -82.02% and lost -80.49% year-on date.

The market cap for RDHL stock reached $33.82 million, with 52.52 million shares outstanding and 34.99 million shares in the current float. Compared to the average trading volume of 2.15M shares, RDHL reached a trading volume of 14710699 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about RedHill Biopharma Ltd. [RDHL]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RDHL shares is $7.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RDHL stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for RedHill Biopharma Ltd. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 31, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on May 18, 2021, representing the official price target for RedHill Biopharma Ltd. stock.

The Average True Range (ATR) for RedHill Biopharma Ltd. is set at 0.07, with the Price to Sales ratio for RDHL stock in the period of the last 12 months amounting to 0.41.

RDHL stock trade performance evaluation

RedHill Biopharma Ltd. [RDHL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.45. With this latest performance, RDHL shares dropped by -51.14% in over the last four-week period, additionally sinking by -82.02% over the last 6 months – not to mention a drop of -89.91% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RDHL stock in for the last two-week period is set at 22.21, with the RSI for the last a single of trading hit 15.03, and the three-weeks RSI is set at 28.44 for RedHill Biopharma Ltd. [RDHL]. The present Moving Average for the last 50 days of trading for this stock 0.8818, while it was recorded at 0.5721 for the last single week of trading, and 1.6412 for the last 200 days.

RedHill Biopharma Ltd. [RDHL]: An insightful look at the core fundamentals

RedHill Biopharma Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.00.

RedHill Biopharma Ltd. [RDHL]: Insider Ownership positions

There are presently around $2 million, or 11.30% of RDHL stock, in the hands of institutional investors. The top three institutional holders of RDHL stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 1,045,023, which is approximately 21.261% of the company’s market cap and around 12.96% of the total institutional ownership; DISCIPLINED GROWTH INVESTORS INC /MN, holding 810,646 shares of the stock with an approximate value of $0.41 million in RDHL stocks shares; and GAGNON SECURITIES LLC, currently with $0.19 million in RDHL stock with ownership of nearly 2.178% of the company’s market capitalization.

Positions in RedHill Biopharma Ltd. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 16 institutional holders increased their position in RedHill Biopharma Ltd. [NASDAQ:RDHL] by around 782,159 shares. Additionally, 19 investors decreased positions by around 1,411,954 shares, while 18 investors held positions by with 1,885,592 shares. The mentioned changes placed institutional holdings at 4,079,705 shares, according to the latest SEC report filing. RDHL stock had 4 new institutional investments in for a total of 404,349 shares, while 6 institutional investors sold positions of 197,381 shares during the same period.


Please enter your comment!
Please enter your name here